Form 4: Prelude Therapeutics Inc. Executive Awarded Stock Options

Peggy Scherle, Chief Scientific Officer of Prelude Therapeutics Inc., was granted stock options for 175,000 shares on February 4, 2025.

Summary

• Peggy Scherle, the Chief Scientific Officer of Prelude Therapeutics Inc., received employee stock options on February 4, 2025.
• The options grant Scherle the right to purchase 175,000 shares of Prelude Therapeutics common stock at an exercise price of $1.11 per share.
• The options vest over a period of four years, with 25% vesting on February 4, 2026, and the remaining 75% vesting monthly thereafter until fully vested, contingent upon Scherle's continued service to the company.
• The options expire on February 4, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it signals confidence in the executive and the company's future.

Positives

• The granting of stock options to the Chief Scientific Officer aligns her interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. The size and vesting schedule of the options are typical for an executive at this level.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their key personnel.
• The vesting schedule of 25% after one year followed by monthly vesting is a common practice to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, indicating that the company is investing in its leadership.
• Employees may be motivated by the fact that executives are incentivized to improve the company's performance.

Key Dates